OXURION (EBR:OXUR) | WebDisclosure

PRESS RELEASE

published on 06/30/2025 at 18:00, 1 year 2 months ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC as it crosses under 10% shareholding threshold by selling voting securities. Company focused on therapeutic innovation and clinical research technologies

Clinical Research Transparency Notification Biopharmaceutical Belgium Oxurion NV
PRESS RELEASE

published on 06/30/2025 at 18:00, 1 year 2 months ago

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC over verkoop van aandelen. Bedrijf combineert therapeutische innovatie met klinisch onderzoekstechnologieën

Transparantiekennisgeving Oxurion NV België Biofarmaceutisch Bedrijf Atlas Special Opportunities II LLC
BRIEF

published on 06/25/2025 at 18:05, 1 year 3 months ago

Oxurion reçoit une notification de transparence d'Atlas Special Opportunities II LLC

Actions Notification Transparence Atlas Special Opportunities Oxurion
BRIEF

published on 06/25/2025 at 18:05, 1 year 3 months ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Notification Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 06/25/2025 at 18:00, 1 year 3 months ago

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC over verkoop van aandelen en onder drempel van 15% gegaan. Bedrijf richt zich op therapeutische innovatie met technologieën voor klinisch onderzoek

Transparantiekennisgeving Aandelen Oxurion NV Atlas Special Opportunities II LLC Therapeutische Innovatie
PRESS RELEASE

published on 06/25/2025 at 18:00, 1 year 3 months ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC indicating a decrease in shareholding below the threshold. The biopharmaceutical company is focused on therapeutic innovation and clinical research technologies

Technology Clinical Research Transparency Notification Biopharmaceutical Oxurion NV
BRIEF

published on 06/19/2025 at 08:35, 1 year 3 months ago

Oxurion to Acquire Preclinical Microbiology CRO in Toulouse

Acquisition Diversification Toulouse Oxurion Microbiology CRO
BRIEF

published on 06/19/2025 at 08:35, 1 year 3 months ago

Oxurion acquiert une CRO en microbiologie préclinique à Toulouse

Acquisition Diversification Toulouse Oxurion CRO En Microbiologie
PRESS RELEASE

published on 06/19/2025 at 08:30, 1 year 3 months ago

Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een preklinische microbiologie-CRO om zich te diversifiëren en zijn aanwezigheid in de regio Toulouse te versterken
Oxurion NV, een biofarmaceutisch bedrijf in Leuven, kondigt intentieovereenkomst voor de overname van onderneming gespecialiseerd in microbiologische diensten aan, ter versterking van expertise en strategie

Stratégie Overname Oxurion NV Biofarmaceutisch Microbiologische Diensten
PRESS RELEASE

published on 06/19/2025 at 08:30, 1 year 3 months ago

Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region
Oxurion NV announces LOI to acquire 70% share capital of preclinical microbiology services company. Economic details of the transaction and growth projections disclosed

Acquisition Transaction Details Growth Projections Oxurion NV Preclinical Microbiology

Published on 09/26/2026 at 01:00, 13 hours 47 minutes ago

Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 13 hours 47 minutes ago

Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 16 hours 32 minutes ago

Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 21 hours 17 minutes ago

Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 23 hours 47 minutes ago

HM Exploration Provides Program Update for the Lewis Pilley's Project

View all ACCESSWIRE

Published on 09/26/2026 at 07:45, 7 hours 1 minute ago

Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 14 hours 45 minutes ago

Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 20 hours 17 minutes ago

029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:15, 20 hours 32 minutes ago

Warren Wise decodes Qiagen’s DNA
Published on 09/25/2026 at 18:00, 20 hours 47 minutes ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26

View all EQS

Published on 09/26/2026 at 07:00, 7 hours 47 minutes ago

Groupe DLSI - Résultat 1er semestre 2026
Published on 09/25/2026 at 18:00, 20 hours 47 minutes ago

COGRA : RAPPORT FINANCIER ANNUEL 2025/26
Published on 09/25/2026 at 18:00, 20 hours 47 minutes ago

COGRA : RAPPORT FINANCIER ANNUEL 2025/26
Published on 09/25/2026 at 17:45, 21 hours 2 minutes ago

COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 21 hours 7 minutes ago

Availability of the 2026 half-year financial report

View all LES ECHOS COMFI WIRE

News